John Jordan

Finanzdirektor/CFO bei Rna Diagnostics, Inc.

Health Technology

Profil

John Jordan has held positions as a Chief Financial Officer and Director at Rna Diagnostics, Inc. and as a Director and Chief Financial Officer at Proteocyte Diagnostics, Inc. Currently, Mr. Jordan holds positions at both companies as their Chief Financial Officer and Director.

Aktive Positionen von John Jordan

Unternehmen	Position	Beginn
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Finanzdirektor/CFO	-
Proteocyte Diagnostics, Inc. Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada.	Finanzdirektor/CFO	-

Alle aktiven Positionen von John Jordan

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von John Jordan im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Health Technology
Proteocyte Diagnostics, Inc. Proteocyte Diagnostics, Inc. Medical SpecialtiesHealth Technology Proteocyte Diagnostics, Inc. develops prognostic oral precancer laboratory, which objectively and accurately detects oral lesions. The company was founded in 2011 and is headquartered in Toronto, Canada.	Health Technology